杨晓宸,关东亮

I型糖尿病是胰岛β细胞损伤引起的不可逆的血糖调控异常疾病，严重威胁人类生命健康。与II型糖尿病治疗不同，I型糖尿病不仅需要对血糖水平进行精确干预，还需对人体自身免疫系统进行监控和调控以减缓胰岛组织损伤。I型糖尿病的药物治疗方案主要围绕胰岛素治疗展开，对于胰岛素治疗不佳的患者缺乏有效药物治疗手段。目前，针对I型糖尿病的迭代创新药物及治疗手段在研发中，包括长效药物及细胞治疗等创新治疗手段有望未来提升I型糖尿病治疗效果。本文就I型糖尿病的发病机制、治疗手段、药物开发状况进行了综述和讨论，并展望了适应症治疗未来发展方向。

I型糖尿病；胰岛素；免疫抑制；胰淀素；细胞治疗

[1] Xu Y,Lu J,Li M,et al.,Diabetes in China part 1:epidemiology and risk factors[J].The Lancet Public Health,2024,9(12):1089-1097 [2] Sun H,Saeedi P,Karuranga S,et al.,IDF Diabetes Atlas:Global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract.2023,183:109-119 [3] 孙肖霄,黄干,谢志国,等.1型糖尿病遗传学研究进展[J].中华医学杂志,2020,100(10):793‑796. [4] Tang X,Yan X,Zhou H,et al.Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes[J]. Diabetes Metab Syndr Obes,2019,12:1527‑1541. [5] DeFronzo R A,Ferrannini E,Groop L,et al.Type 2 diabetes mellitus[J].Nature reviews Disease primers,2015,1(1):1-22. [6] 中华医学会糖尿病学分会,中国医师协会内分泌代谢科医师分会,中华医学会内分泌学分会,等.中国1型糖尿病诊治指南(2021版)[J].中华糖尿病杂志,2022,14(11):1143-1250. [7] American Diabetes Association.Standards of Care in Diabetes—2024[J].Diabetes Care,2024,47(Supplement_1) [8] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(01):16-139. [9] Schaffner H,Wiener J,DeLuca A,et al.Insulin icodec:A novel once-weekly treatment for diabetes[J].Diabetic Medicine,2024,4 1(10):e15414. [10] Zamboni F,Collins M N.Cell based therapeutics in type 1 diabetes mellitus[J].International journal of pharmaceutics,2017, 521(1-2):346-356. [11] Herold K C,Bundy B N,Long S A,et al.An anti-CD3 antibody,teplizumab,in relatives at risk for type 1 diabetes[J].New England Journal of Medicine,2019,381(7):603-613. [12] Gruessner RW,Gruessner AC.The current state of pancreas transplantation[J].Nat Rev Endocrinol,2013,9(9):555‑562 [13] Holleman F,Hoekstra J B L.Insulin lispro[J].New England Journal of Medicine,1997,337(3):176-183. [14] Bramlage P,Tittel S R,Müther S,et al.A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes[J].Acta Diabetologica,2022,59(11):1453-1460. [15] Hilgenfeld R,Seipke G,Berchtold H,et al.The evolution of insulin glargine and its continuing contribution to diabetes care[J]. Drugs,2014,74:911-927. [16] Mathiesen E R,Alibegovic A C,Corcoy R,et al.Insulin degludec versus insulin detemir,both in combination with insulin aspart,in the treatment of pregnant women with type 1 diabetes(EXPECT):an open label,multinational,randomised,controlled,non-inferiority trial[J].The Lancet Diabetes&Endocrinology,2023,11(2):86-95. [17] Perdigoto A L,Preston-Hurlburt P,Clark P,et al.Treatment of type 1 diabetes with teplizumab:clinical and immunological follow-up after 7 years from diagnosis[J].Diabetologia,2019,62:655-664. [18] Buddhavarapu V,Dhillon G,Grewal H,et al.Safety of teplizumab in patients with high-risk for diabetes mellitus type 1:A systematic review[J].World Journal of Diabetes,2024,15(8):1793. [19] Nishimura E,Pridal L,Glendorf T,et al.Molecular and pharmacological characterization of insulin icodec:a new basal insulin analog designed for once-weekly dosing[J].BMJ Open Diabetes Research and Care,2021,9(1):e002301. [20] Lisco G,De Tullio A,De Geronimo V,et al.Once-weekly insulin icodec in diabetes mellitus:a systematic review and meta-analysis of randomized clinical trials(ONWARDS Clinical Program)[J].Biomedicines,2024,12(8):1852. [21] Ryan G J,Jobe L J,Martin R.Pramlintide in the treatment of type 1 and type 2 diabetes mellitus[J].Clinical therapeutics,2005, 27(10):1500-1512. [22] Kruse T,Hansen J L,Dahl K,et al.Development of cagrilintide,a long-acting amylin analogue[J].Journal of medicinal chemistry,2021, 64(15):11183-11194. [23] Frias J P,Deenadayalan S,Erichsen L,et al.Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes:a multicentre,randomised,double-blind,active-controlled,phase 2 trial[J].The Lancet,2023,402 (10403):720-730. [24] Shahjalal H M,Abdal Dayem A,Lim K M,et al.Generation of pancreaticβcells for treatment of diabetes:advances and challenges[J]. Stem cell research&therapy,2018,9:1-19. [25] Harrison C.First cell therapy for diabetes approved[J].nature biotechnology,2023,41:1035-1046. [26] Rios P,McGarrigle J J,Lamonica G,et al.35-OR:Lantidra,First FDA-approved cellular therapy to treat type 1 diabetes[J].Diabetes, 2024,73(Supplement_1).

点击下载PDF